These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 17109993

  • 1. Gadolinium deposition in nephrogenic fibrosing dermopathy.
    Boyd AS, Zic JA, Abraham JL.
    J Am Acad Dermatol; 2007 Jan; 56(1):27-30. PubMed ID: 17109993
    [Abstract] [Full Text] [Related]

  • 2. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.
    High WA, Ayers RA, Chandler J, Zito G, Cowper SE.
    J Am Acad Dermatol; 2007 Jan; 56(1):21-6. PubMed ID: 17097388
    [Abstract] [Full Text] [Related]

  • 3. Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis.
    Thakral C, Abraham JL.
    J Cutan Pathol; 2009 Dec; 36(12):1244-54. PubMed ID: 19602073
    [Abstract] [Full Text] [Related]

  • 4. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, Quaglia M, Stratta P.
    J Nephrol; 2008 Dec; 21(3):324-36. PubMed ID: 18587720
    [Abstract] [Full Text] [Related]

  • 5. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis.
    Hamilton-Persaud K, Ezell LD, Macklin JG.
    Nephrol Nurs J; 2007 Dec; 34(3):283-7; quiz 288. PubMed ID: 17644872
    [Abstract] [Full Text] [Related]

  • 6. Time-dependent decrement of dermal gadolinium deposits and significant improvement of skin symptoms in a patient with nephrogenic systemic fibrosis after temporary renal failure.
    Schäd SG, Heitland P, Kühn-Velten WN, Gross GE, Jonas L.
    J Cutan Pathol; 2013 Nov; 40(11):935-44. PubMed ID: 24102613
    [Abstract] [Full Text] [Related]

  • 7. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS, Sanyal S, Abraham JL.
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [Abstract] [Full Text] [Related]

  • 8. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis.
    Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P.
    Br J Dermatol; 2008 Feb; 158(2):273-80. PubMed ID: 18067485
    [Abstract] [Full Text] [Related]

  • 9. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature.
    Lim YL, Lee HY, Low SC, Chan LP, Goh NS, Pang SM.
    Clin Exp Dermatol; 2007 Jul; 32(4):353-8. PubMed ID: 17433041
    [Abstract] [Full Text] [Related]

  • 10. Gadolinium and nephrogenic systemic fibrosis: association or causation.
    Kurtkoti J, Snow T, Hiremagalur B.
    Nephrology (Carlton); 2008 Jun; 13(3):235-41. PubMed ID: 18221255
    [Abstract] [Full Text] [Related]

  • 11. Strong association between the use of gadolinium-based contrast agents with nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis.
    Jamboti J.
    Intern Med J; 2007 Jul; 37(7):508-9; author reply 509. PubMed ID: 17547734
    [No Abstract] [Full Text] [Related]

  • 12. Nephrogenic systemic fibrosis: an overview.
    Cowper SE.
    J Am Coll Radiol; 2008 Jan; 5(1):23-8. PubMed ID: 18180005
    [Abstract] [Full Text] [Related]

  • 13. Nephrogenic systemic fibrosis in advanced chronic kidney disease: a single hospital's experience in Taiwan.
    Chen W, Huang SL, Huang CS, Tsai MC, Lai HM, Lui CC, Eng HL, Chang HW, Lee CH, Chuang FR.
    Eur J Dermatol; 2009 Jan; 19(1):44-9. PubMed ID: 19059824
    [Abstract] [Full Text] [Related]

  • 14. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
    Grobner T, Prischl FC.
    Semin Dial; 2008 Jan; 21(2):135-9. PubMed ID: 18226001
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2007 Feb 23; 56(7):137-41. PubMed ID: 17318112
    [Abstract] [Full Text] [Related]

  • 18. Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling.
    Deng A, Martin DB, Spillane A, Chwalek J, St Surin-Lord S, Brooks S, Petrali J, Sina B, Gaspari A, Kao G.
    J Cutan Pathol; 2010 Feb 23; 37(2):204-10. PubMed ID: 19341434
    [Abstract] [Full Text] [Related]

  • 19. Findings of osseous sclerotic bodies: a unique sequence of cutaneous bone formation in nephrogenic systemic fibrosis.
    Kartono F, Basile A, Roshdieh B, Schwimer C, Shitabata PK.
    J Cutan Pathol; 2011 Mar 23; 38(3):286-9. PubMed ID: 20726931
    [Abstract] [Full Text] [Related]

  • 20. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis in 2 patients with end-stage renal disease on hemodialysis.
    Kim RH, Ma L, Hayat SQ, Ahmed MM.
    J Clin Rheumatol; 2006 Jun 23; 12(3):134-6. PubMed ID: 16755242
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.